Altimmune Reports $22.6 Million Net Loss in Q1 2026, No Revenue Generated

Altimmune, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $22.6 million, an increase from the $19.6 million loss recorded in the same period of 2025. The company did not generate any revenue during this quarter, a decline from the $5,000 reported in the prior year. Total operating expenses rose to $24.2 million, up 11% from $21.8 million in the previous year, primarily driven by increased research and development costs associated with ongoing clinical trials and higher general and administrative expenses.

The company's cash and cash equivalents, along with short-term investments, totaled $331.6 million as of March 31, 2026, a significant increase from $278.2 million at the end of 2025. This growth was largely attributed to successful financing activities, including a registered direct offering in January 2026 that raised approximately $70.3 million and an at-the-market offering that generated $8.7 million in proceeds. Altimmune's total liabilities decreased to $51.6 million from $55.0 million at the end of the previous fiscal year, reflecting a reduction in current liabilities.

In terms of operational developments, Altimmune is advancing its lead product candidate, pemvidutide, which is in late-stage clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company received Breakthrough Therapy Designation from the FDA for pemvidutide in January 2026, based on positive data from the IMPACT Phase 2b trial. The company is preparing to initiate the PERFORMA Phase 3 trial for MASH in the second half of 2026, following alignment with the FDA on the study protocol.

The company’s employee headcount has increased, reflecting its ongoing recruitment efforts to support its clinical programs and operational needs. As of March 31, 2026, Altimmune had 130.2 million shares of common stock outstanding, up from 110.9 million shares at the end of 2025, indicating a strategic focus on raising capital through equity offerings. The company continues to explore additional financing options to support its clinical trials and operational activities, as it has not yet generated revenue from product sales.

Looking ahead, Altimmune remains focused on executing its clinical trials and advancing pemvidutide through the regulatory process. The company anticipates that its current cash position, bolstered by recent financing activities, will be sufficient to fund operations for at least the next twelve months. However, it acknowledges the need for ongoing capital to support its long-term growth strategy and clinical development plans.